GEN

Data Robustness and Reproducibility in Gene Editing Applications: Today’s Limits and Tomorrow’s Potential

CRISPR’s use has vast potential in basic research to add to the understanding of cellular activity and in healthcare for precision therapies for today’s untreatable diseases. To date, some 30 clinical ...
GEN

Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy “Signals” in Two Patients

Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Nature

CRISPECTOR provides accurate estimation of genome editing translocation and off-target activity from comparative NGS data

Controlling off-target editing activity is one of the central challenges in making CRISPR technology accurate and applicable in medical practice. Current algorithms for analyzing off-target activity ...
GPS World

1Spatial Launches 1Edit Spatial Data Editing Solution

No audio available for this content. 1Spatial has launched 1Edit, a touchscreen compatible solution that offers fast and intuitive data-editing in the field or office, 1Spatial said. Trialed by ...
Nature

LoDEI: a robust and sensitive tool to detect transcriptome-wide differential A-to-I editing in RNA-seq data

About 170 modifications of ribonucleotides are known to affect biological functions significantly, and misregulation is associated with a growing number of diseases 1,2. RNA editing is an RNA ...
FierceBiotech

UPDATED: Editas' gene editing data have company touting prime time based on early vision improvement signals, but questions remain

Editas Medicine may have been first to enter the clinic with a gene-editing therapy, but it was beaten to the finish line by Intellia with first-in-human results in June. But it’s not a competition.